UB neuroscientists have identified the binding site of low-dose ketamine, providing critical insight into how the medication ...

Since 2005, the American Psychiatric Association has recommended BLT as a treatment option for patients with major depressive ...

The global major depressive disorder (MDD) treatment market is expected to experience steady growth, projected to develop at ...

Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when ...

Bright light therapy, a standard treatment for seasonal depression, may also help people who experience depression year-round ...

Depression and anxiety rank among the top global health challenges. Since 1990, these disorders have surged, placing them in ...

Patients with non-seasonal depression who were treated with bright light therapy reported a 40% remission rate, according to a recent study.

Cybin (TSE:CYBN) has released an update. Cybin Inc. is set to present promising 12-month data from its Phase 2 study of CYB003, aimed at ...

Cybin Inc. CYBN has launched its Phase 3 pivotal program called PARADIGM, which is aimed at testing the efficacy of its lead ...

Repetitive transcranial magnetic stimulation offers rapid depression relief for patients unresponsive to conventional ...

de Filippis, R. and Al Foysal, A. (2024) Case Report: The Role of Monoamine Oxidase Inhibitors in Treating Resistant Depression. Open Access Library Journal, 11, 1-12. doi: 10.4236/oalib.1112369 .